US Patent

US11654196 — Dosing regimens for echinocandin class compounds

Method of Use · Assigned to Cidara Therapeutics Inc · Expires 2032-03-02 · 6y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects dosing regimens and oral dosage formulations for administering echinocandin class compounds, such as rezafungin acetate.

USPTO Abstract

The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.

Drugs covered by this patent

rezafungin-acetate (REZAFUNGIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3566`	—	rezafungin-acetate

Patent Metadata

Patent number: US11654196
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Cidara Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.